Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 22/6/2017
SIETES contiene 91846 citas

 
 
 1 a 20 de 14353 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Li L, Geraghty OC, Mehta Z, Rotwell PM, on behalf of the Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 2017:13 de junio. [Ref.ID 101638]
2. Cita con resumen
Patorno E, Huybrechts KF, Bateman BT, Cohen JM, Desai RJ, Mogun H, Cohen LS, Hernández-Díaz S. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med 2017;376:2245-54. [Ref.ID 101629]
3.Tiene citas relacionadas Cita con resumen
Schoenfeld AJ, Redberg RF. The value of using registries to evaluate randomized clinical trial study populations. JAMA Intern Med 2017;177:889. [Ref.ID 101623]
4.Tiene citas relacionadas Cita con resumen
Maddox TM, Tang F, Downs JR, Masoudi FA, Virani SS, Daugherty SL, Rumsfeld JS. Applicability of the IMPROVE-IT trial to current patients with acute coronary syndrome: an NCDR research to practice project. JAMA Intern Med 2017;177:887-9. [Ref.ID 101622]
5. Cita con resumen
Dondo TB, Hall M, West RM, Jemberg T, Lindahl B, Bueno H, Danchin N. ß-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol 2017;69:2710-20. [Ref.ID 101613]
6.Tiene citas relacionadas Cita con resumen
Curfman G. Risks of statin therapy in older adults. JAMA Intern Med 2017:22 de mayo. [Ref.ID 101591]
7.Tiene citas relacionadas Cita con resumen
Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS, for the ALLHAT Collaborative Research Group. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults. The ALLHAT-LLT randomized clinical trial. JAMA Intern Med 2017:22 de mayo. [Ref.ID 101590]
8. Cita con resumen
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22. [Ref.ID 101586]
9.Enlace a cita original Cita con resumen
Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, Brophy JM. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909. [Ref.ID 101568]
10. Cita con resumen
Trifirò G, de Ridder M, Sultana J, Oteri A, Rijnbeek P, Pecchioli S, Mazzaglia G, Bezemer I, Garbe E, Schink T, Poluzzi E, Froslev T, Molokhia M, Diemberger I, Sturkenboom M. Use of azithromycin and risk of ventricular arrhytmia. CMAJ 2017;189:E560-8. [Ref.ID 101536]
11. Cita con resumen
Anónimo. Lévosimendan et décompensation d'une insuffisance cardiaque. Prescrire 2017;37:245-7. [Ref.ID 101528]
12. Cita con resumen
Anónimo. Drugs for hypertension. The Medical Letter on Drug and Therapeutics Bulletin 2017;59:41-8. [Ref.ID 101527]
13.Tiene citas relacionadas Cita con resumen
Grosser T. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2017;376:1389-90. [Ref.ID 101526]
14.Enlace a cita original Cita con resumen
Biffi A, Scotti L, Corrao G. Use of antidepressants and the risk of cardiovascular and cerebrovascular disease: a meta-analysis of observational studies. Eur J Clin Pharmacol 2017;73:487-97. [Ref.ID 101517]
15. Cita con resumen
Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P, for the EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017;376:1211-22. [Ref.ID 101509]
16. Cita con resumen
Anónimo. Anticoagulation for elderly patients at high risk for falls with atrial fibrillation. The Medical Letter on Drug and Therapeutics Bulletin 2017;59:35-6. [Ref.ID 101488]
17.Enlace a cita original Cita con resumen
Stolk LM, de Vries F, Ebbelaar C, de Boer A, Schalekamp T, Souverein P, ten Cate-Hoek A, Burden AM. Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. Br J Clin Pharmacol 2017:marzo. [Ref.ID 101480]
18.Enlace a cita originalTiene citas relacionadas
Valente M, Bhandari S. Renal function after new treatment with renin-angiotensin system blockers. BMJ 2017;356:j1122. [Ref.ID 101474]
19.Enlace a cita originalTiene citas relacionadas Cita con resumen
Schmidt M, Mansfield KE, Bhaskaran K, Nitsch D, Sørensen HT, Smeeth L, Tomlinson LA. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ 2017;356:j791. [Ref.ID 101473]
20.Enlace a cita original Cita con resumen
Yasmina A, de Boer A, Deneer VHM, Souverein PC, Klungel OH. Patterns of antiplatelet drug use after a first myocardial infarction during a 10-year period. Br J Clin Pharmacol 2017;83:632-41. [Ref.ID 101464]
Seleccionar todas
 
 1 a 20 de 14353 siguiente >>